echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > Blood: Multiple CRBN variants associated with amine/pomadamine access resistance!

    Blood: Multiple CRBN variants associated with amine/pomadamine access resistance!

    • Last Update: 2021-01-24
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    The emergence of resistance to all available therapies is a major challenge in improving myeloma survival.
    Cereblon (CRBN) is an important binding protein for a variety of drugs, including immunomodulation drugs (IMiDs) widely used in myeloma and new CRBN E3 connective enzyme regulators (CELMoDs), as well as certain protein hydrolysis (PROTAC) drugs that are being developed for the treatment of a range of diseases.
    study used genome-wide sequencing (WGS) data from 455 patients and RNA sequencing (RNAseq) data from 655 patients from three different queues: a new confirmed queue (WGS, n=198; RNAseq, n=437) ), a len-difficult queue (WGS, n=203; RNAseq, n=176) and a Pomadamine (POM) - Resusced Queue (WGS, n=54; RNAseq, n=42).
    Analysis of CRBN variation in different patients found that with the gradual exposure of IMiD, the frequency of three CRBN variants (i.e., point mutation, copy loss/structural variation, and a specific variant transcript (exon scissors no. 10) increased gradually until almost one-third of patients developed CBN mutations when they were resistant to POM.
    CRBN mutations were associated with prognosis in patients with multiple myeloma Researchers found that all three CRBN variants were associated with poor prognosis when POM was used in patients who were already resistant to LEN, including those with lost gene replication and structural variation, a finding that had not been described before.
    , this study is the first and largest comprehensive analysis of CBRN mutations in myeloma patients during treatment.
    results of this study will help guide patients to choose CRBN targeted drugs for sequentia therapy.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.